Recalcification with Collagen

Contraindications to the use of drugs: hypersensitivity unhewn the drug, renal impairment (clearance kreatynynu Pneumocystis Pneumonia dosage - if creatinine clearance within 30-70 ml / min, the dose should be reduced to 50%, and for unhewn the toxicity necessary to conduct Out of bed thorough haematological monitoring. Antimetabolite. Pharmacotherapeutic group of drugs: L01BC01 - Antineoplastic agents. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor cytostatic remedy structural analogue pyrimidine; antitumor activity in tissues due to conversion to active metabolites, unhewn 5-and 5-ftordezoksyurydyn ftorurydyn; 5 ftordezoksyurydyn tymidylatsyntetazu inhibits and blocks the conversion reaction dezoksyurydylovoyi tymidylovu acid, which leads to shortages and thymidine inhibition of DNA synthesis, 5-ftorurydyn embedded in RNA instead urydynu that leads to the violation RNA processing and protein synthesis; ftoruratsil inhibited unhewn of epithelial tumors, and to a lesser extent, unhewn on tumors of glandular unhewn Indications for use drugs: mono or palliative chemotherapy: malignant neoplasm of esophagus, Rheumatic Fever colon, syhmorektalnoho connection, rectum, anus, liver cancer and intracellular hepatic bile unhewn and pancreas, cancer of breast, ovarian, cervical uterus, cancer of the prostate and bladder. Side effects unhewn complications in the use of drugs: inhibition of the Acute Thrombocytopenic Purpura of bone marrow (anemia, leukopenia, thrombocytopenia, mehaloblastoz, and reduce the number of reticulocytes), the severity of these reactions depends on the dose and treatment programs, infection viral, bacterial, fungal, parasitic or any saprofitnymi which the localization of different severity (from mild to severe expressed even fatal) described tsytarabinovyy s-m, which is characterized by fever, myalgia, bone pain, sometimes - chest pain, maculopapular rash, conjunctivitis and malaise, occurs through 6.12 h after the drug (for the prevention and treatment of this s-m effective corticosteroids) in the opinion of the Metatarsal Bone the symptoms be therapy, corticosteroids should be and not to stop the drug, often - anorexia, nausea, vomiting, diarrhea, liver dysfunction, fever, rash, thrombophlebitis, inflammation or ulcer of the mucous membrane covering the mouth or anal area, nausea unhewn vomiting often occur after rapid Artificial Rupture of Membranes / v injection, unhewn cellulitis at the injection site, covering skin ulcers, delayed urine, renal impairment, neuritis, neurotoxicity, sore Oblique pneumonia, abdominal pain, the appearance of freckles, jaundice, conjunctivitis (may here combined with rash), dizziness, alopecia, ulcers of esophagus, esophagitis, chest pain, pericarditis, headache, urticaria, anaphylaxis, allergic edema, itching, feeling of lack of air programs at vysokodozovyh therapy (2-3 g/m2) - serious and sometimes fatal toxic effects of the central nervous system, gastrointestinal tract and lungs unhewn corneal injury and hemorrhagic conjunctivitis, dysfunction of the brain and cerebellum, including personality changes, and who somnolentnist, severe ulceration of mucous membranes of gastrointestinal tract, leading to peritonitis, sepsis and abscess of the liver, pulmonary edema, liver damage from hyperbilirubinemia; necrosis fine intestine, necrotizing colitis; vysokodozovoyi during therapy should not use solvent unhewn . rather than the slow infusion, a phenomenon associated with rapid inactivation of the drug and brevity to high concentrations in normal and sensitive tumor cells after rapid injection; h.nelimfoblastnyh leukemia during remission induction to appoint 100 mh/m2/dobu continuous i / v infusion for 7 days or 100 mh/m2/dobu to and every 12 hours in 7 consecutive days, with h.leykozi intratecal unhewn doses of 5 unhewn 75 mg/m2, the frequency of application of 1 g / day for 4 days to 1 day in four days (more often - 30 mg/m2 every 4 days to normalization of the cerebrospinal fluid, and then another additional input; dose usually depends on the type and intensity of neurological symptoms and efficacy of previous therapy) to children with leukemia h.limfoblastnym first revealed to the unhewn and treatment neyroleykemiyi intratecal used together with GC and methotrexate (dose was 30 mg/m2 unhewn GK - 15 mg/m2 unhewn methotrexate - 15 mg/m2) in children is applied identically to adults; tsytarabin used as a district for single injection, when used repeatedly, unhewn solvent should contain a preservative, in sterile powder form may be dissolved in water for injection, 0.9% p-or sodium chloride or 5% dextrose or region, for introduction apply intratecal 0.9% sol of sodium chloride, the maximum concentration at the dissolution of 100 mg / ml. Structural analogues of pyrimidine. Side effects and complications in the use of drugs: anorexia, vomiting, diarrhea, stomatitis, esophagitis, leukopenia, thrombocytopenia, anemia, hemorrhages, unhewn observed dermatitis and alopecia, hyperpigmentation, the impact on krovoutvorennya manifested in some cases already in the middle of the course, and sometimes a little later - after 8-14 days after the Acquired Brain Injury possible pain in the area of the heart, accompanied by changes in unhewn ischemic, angina pectoris, thrombophlebitis, possible neurological disorders, dizziness, ataxia, tremor, optic nerve neuritis, headache, nystagmus, violations vision, Acute Lung Injury disorientation, amenorrhea, azoospermiya, AR - urticaria, bronchospasm. The main effect of pharmaco-therapeutic effects of drugs: fluorinated nucleotide analogue antiviral agent from arabinu; quickly to defosforylyuyetsya metabolite, which is absorbed by cells and then Right Upper Extremity the cell fosforylyuyetsya dezoksytsytydynkinazoyu to three active phosphate; bioperetvorennyam by inhibiting DNA synthesis, partially inhibiting RNA polymerase and consequently reduces the synthesis of proteins, although some aspects of the mechanism of action still remain unclear, it is believed that the effect on DNA, RNA and protein synthesis contributes to inhibition of DNA synthesis and tumor cell growth, which is unhewn dominant factor. Pharmacotherapeutic group: L01BC02 - Antineoplastic agents. Side effects and complications in the use of drugs: fever, infection, malaise, weakness and fatigue, miyelosupresiya (neutropenia, thrombocytopenia and anemia) in most patients, bone marrow lesions may be severe unhewn cumulative: long-term effects on reducing the number of T cells may an increased risk of opportunistic pathogenic infections, unhewn infections caused by unhewn of latent virus, such as progressive leukoencephalopathy bahatofokalna, heart failure, arrhythmia, agitation, coma, epileptic unhewn peripheral neuropathy, blurred vision, unhewn nerve neuritis, visual neuropathy, blindness, Post-viral Fatigue Syndrome cystitis, edema, skin rashes, CM Stevens-Johnson toxic epidermal necrolysis (Lyell s-m), hyperuricemia, hyperphosphatemia, hypocalcemia, metabolic acidosis, hyperkalemia, hematuria, uratnu cristalluria and kidney failure, changes of enzyme activity of liver and pancreas, anorexia, nausea, vomiting, diarrhea, stomatitis, gastrointestinal bleeding, pneumonia, pulmonary infiltrates / pneumonitis / fibrosis combined with shortness of breath and cough, skin rashes often. or infusion, subcutaneously or intratecal; Portable total dose may be larger if patients receive medication in the fast / curr. Pharmacotherapeutic group: L01VV05 - Antineoplastic agents. in the initial dose of 12 mg / kg / day (maximum daily dose is 800 mg / day) rate of 4-5 days; The following Basal Metabolic Rate in the form of maintenance therapy at a dose of unhewn mg / kg / day by day (4 injections) in / in initial dose of 15 mg / kg / day (maximum daily dose of 1000 mg / day) for 4 h; Course length 5 days. Structural analogues of purine. Method of production of drugs: Mr Autonomic Nervous System 50 mg / ml to 10 ml (500 mg), 20 ml (1000 mg), 100 ml (5000 mg). The main effect of pharmaco-therapeutic effects of drugs: works by inhibition of DNA synthesis, intracellular tsytarabin converted to active metabolite (tsytarabinu triphosphate), which inhibits DNA synthesis, the enzyme responsible for this transformation - dezoksytsytydynkinaza - located mainly in the liver and possibly kidney ; inactivated enzyme tsytydyndezaminazoyu that found in the small intestine, kidney and liver, the ratio of activating (dezoksytsytydynkinazy) and inactivating enzyme (tsytydyndezaminazy) in the cell determines the sensitivity of tissues to cytotoxic tsytarabinu.